These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Papillary renal cell carcinoma: A review of the current therapeutic landscape. Courthod G; Tucci M; Di Maio M; Scagliotti GV Crit Rev Oncol Hematol; 2015 Oct; 96(1):100-12. PubMed ID: 26052049 [TBL] [Abstract][Full Text] [Related]
3. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Harshman LC; Choueiri TK Cancer J; 2013; 19(4):316-23. PubMed ID: 23867513 [TBL] [Abstract][Full Text] [Related]
5. Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib. Stein MN; Hirshfield KM; Zhong H; Singer EA; Ali SM; Ganesan S Eur Urol; 2015 Feb; 67(2):353-4. PubMed ID: 25457019 [No Abstract] [Full Text] [Related]
6. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review. Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391 [TBL] [Abstract][Full Text] [Related]
7. Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines. Yang Y; Ricketts CJ; Vocke CD; Killian JK; Padilla-Nash HM; Lang M; Wei D; Lee YH; Wangsa D; Sourbier C; Meltzer PS; Ried T; Merino MJ; Metwalli AR; Ball MW; Srinivasan R; Linehan WM Genes Chromosomes Cancer; 2021 Jun; 60(6):434-446. PubMed ID: 33527590 [TBL] [Abstract][Full Text] [Related]
8. Kidney cancer pathology in the new context of targeted therapy. Allory Y; Culine S; de la Taille A Pathobiology; 2011; 78(2):90-8. PubMed ID: 21677472 [TBL] [Abstract][Full Text] [Related]
10. The molecular characterization and therapeutic strategies of papillary renal cell carcinoma. Chen Q; Cheng L; Li Q Expert Rev Anticancer Ther; 2019 Feb; 19(2):169-175. PubMed ID: 30474436 [No Abstract] [Full Text] [Related]
11. Oncotargets in different renal cancer subtypes. Moch H; Montironi R; Lopez-Beltran A; Cheng L; Mischo A Curr Drug Targets; 2015; 16(2):125-35. PubMed ID: 25619751 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma. Pahwa R; Dubhashi J; Singh A; Jailwala P; Lobanov A; Thomas CJ; Ceribelli M; Wilson K; Ricketts CJ; Vocke CD; Wells C; Bottaro DP; Linehan WM; Neckers L; Srinivasan R J Exp Clin Cancer Res; 2022 Jun; 41(1):208. PubMed ID: 35754026 [TBL] [Abstract][Full Text] [Related]
13. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. Gordon MS; Hussey M; Nagle RB; Lara PN; Mack PC; Dutcher J; Samlowski W; Clark JI; Quinn DI; Pan CX; Crawford D J Clin Oncol; 2009 Dec; 27(34):5788-93. PubMed ID: 19884559 [TBL] [Abstract][Full Text] [Related]
14. The genetic basis of cancer of the kidney. Linehan WM; Walther MM; Zbar B J Urol; 2003 Dec; 170(6 Pt 1):2163-72. PubMed ID: 14634372 [TBL] [Abstract][Full Text] [Related]
15. Molecular genetics of renal carcinogenesis. Walker C Toxicol Pathol; 1998; 26(1):113-20. PubMed ID: 9502393 [TBL] [Abstract][Full Text] [Related]
16. Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population. Lindor NM; Dechet CB; Greene MH; Jenkins RB; Zincke MT; Weaver AL; Wilson M; Zincke H; Liu W Genet Test; 2001; 5(2):101-6. PubMed ID: 11551094 [TBL] [Abstract][Full Text] [Related]
17. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227 [TBL] [Abstract][Full Text] [Related]
18. Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. Diamond JR; Salgia R; Varella-Garcia M; Kanteti R; LoRusso PM; Clark JW; Xu LG; Wilner K; Eckhardt SG; Ching KA; Lira ME; Schoenmakers EF; Christensen JG; Camidge DR J Clin Oncol; 2013 Jun; 31(16):e254-8. PubMed ID: 23610116 [No Abstract] [Full Text] [Related]
19. The prospect of precision therapy for renal cell carcinoma. Ciccarese C; Brunelli M; Montironi R; Fiorentino M; Iacovelli R; Heng D; Tortora G; Massari F Cancer Treat Rev; 2016 Sep; 49():37-44. PubMed ID: 27453294 [TBL] [Abstract][Full Text] [Related]
20. Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. Choueiri TK; Plimack E; Arkenau HT; Jonasch E; Heng DYC; Powles T; Frigault MM; Clark EA; Handzel AA; Gardner H; Morgan S; Albiges L; Pal SK J Clin Oncol; 2017 Sep; 35(26):2993-3001. PubMed ID: 28644771 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]